Abstract P05-02: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)
Year: 2021
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Institutions: UC Davis Comprehensive Cancer Center, University of California, Davis, Johns Hopkins University, Johns Hopkins Medicine, Washington University in St. Louis, Alvin J. Siteman Cancer Center, The University of Texas MD Anderson Cancer Center, Indiana University School of Medicine, Duke University, Norwalk Hospital, Nuvance Health, University of Michigan, Michigan Medicine, Amgen (United States), University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200096031